Welcome to BioSeeker Group!

Triple Analysis: Melanoma, Apoptosis and Peptides

Additional Information

Published Date Jun 12, 2013
Special Offer

You can deduct the full value of this report within 30 days of purchase towards a Cancer Highlights subscription.
Read more about becoming a Cancer Highlights subscriber here.

Pages 3811
PDF Fact Sheet View Fact Sheet for the report Triple Analysis: Melanoma, Apoptosis and Peptides in PDF
Format PDF
Publisher BioSeeker Group
Product Line

Find the Triple Analysis Report in oncology which best suits your needs by selecting any three (3) out of these 14 high impact Cancer Focus Areas.

Availability: In stock

$3,450.00

Quick Overview

This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Melanoma), one mechanism/target/effect area (Apoptosis) and one compound specific area (Peptides).

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Melanoma, Apoptosis and Peptides.

    To find out more about Triple Analysis: Melanoma, Apoptosis and Peptides, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Melanoma, Apoptosis and Peptides is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Melanoma), one mechanism/target/effect area (Apoptosis) and one compound specific area (Peptides). Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: Melanoma
The melanoma drug report part comprises defined and up to date development strategies for 282 drugs within the portfolio of 164 companies world-wide, from Ceased to Marketed. The report extensively analyses their 226 identified drug targets, organized into 187 drug target strategies, and assesses them in melanoma.
This part is based on the following publication:
Melanoma Drug Development Analysis: From First-in-Class to Best-in-Class?

Part II: Apoptosis
The apoptotic cancer drug report part comprises defined and up to date development strategies for 234 drugs in oncology within the portfolio of 158 companies world-wide, from Ceased to Marketed. The report extensively analyses their 181 identified drug targets, organized into 157 drug target strategies, and assesses them in 69 cancer indications.
This part is based on the following publication:
Commercializing Apoptotic Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others

Part III: Peptides
The peptide drug report part comprises defined and up to date development strategies for 171 drugs in oncology within the portfolio of 114 companies world-wide, from Ceased to Marketed. The report extensively analyses their 132 identified drug targets, organized into 109 drug target strategies, and assesses them in 62 cancer indications.
This part is based on the following publication:
Cancer Peptides: From First-in-Class to Best-in-Class?

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug’s properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area strategies

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.

Key Topics Covered:

Part I: Melanoma
5.1 The Scope of this Report 26
6 Consider the Therapeutic Target Among Melanoma Drugs for the Highest Therapeutic Outcome and Return on Investment (226 Drug Targets) 30-467
7 First-in-Class and Me-too Analysis of Melanoma Drugs (187 Drug Target Strategies and 282 Drugs) 468-677
8 Is First-in-Class the Best-in-Class? 488-678
9 Compound Strategies at Work: Competitive Benchmarking of Melanoma Drugs by Compound Strategy (7 Compound Strategies) 679-710
10 The Competition Through Close Mechanistic Approximation of Melanoma Drugs 711
11 Pipeline and Portfolio Planning: Competitive Benchmarking of the Melanoma Drug Pipeline by Company (164 Companies and 282 Drugs) 716-1165
12 Disclaimer 1166
Figures: Includes 5 Figures
Tables: Includes 222 Tables
Total Number of Pages: 1,181

Part II: Apoptosis
5.1 The Scope of this Report 33
6 Consider the Therapeutic Target Among Apoptotic Drugs in Oncology for the Highest Therapeutic Outcome and Return on Investment (181 Drug Targets) 37-416
7 Emerging New Products to Established Ones: Drug Target Strategies of Apoptotic Drugs in Oncology by their Highest Stage of Development (157 Drug Target Strategies and 234 Drugs) 417-622
8 Compound Strategies at Work: Competitive Benchmarking of Apoptotic Cancer Drugs by Compound Strategy(7 Compound Strategies) 623-660
9 Selecting Indication for Apoptotic Drugs in Oncology (69 Cancer Indications) 661-776
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Apoptotic Drug Pipeline in Oncology by Investigator (158 Investigators and 234 Drugs) 777-1601
Disclaimer 1602
11 Drug Index 1603
12 Company Index 1611
Figures: Includes 7 Figures
Tables: Includes 315 Tables
Total Number of Pages: 1,617

Part III: Peptides
5.1 The Scope of this Report 27
6 Consider the Therapeutic Target Among Peptide Drugs in Cancer for the Highest Therapeutic Outcome and Return on Investment (132 Drug Targets) 31-252
7 First-in-Class and Me-too Analysis of Peptide Drugs in Cancer (109 Drug Target Strategies and 171 Drugs) 253-267
8 Is First-in-Class the Best-in-Class? (109 Drug Target Strategies and 171 Drugs) 268-387
9 The Competition through Close Mechanistic Approximation of Peptide Drugs in Cancer 388
10 Selecting Indication for Peptide Drugs in Oncology ( 62 Cancer Indications) 391-475
11 Pipeline and Portfolio Planning: Competitive Benchmarking of the Cancer Peptide Drug Pipeline by Investigator (114 Investigators and 171 Drugs) 476-1001
12 Disclaimer 1002
Figures: Includes 5 Figures
Tables: Includes 232 Tables
Total Number of Pages: 1,013

This Report Includes the Following Companies:
3SBio
7TM Pharma
AB Science
Abbott
AbbVie
Abiogen
Acceleron Pharma
Access
Actelion
Adherex
Advanced Life Sciences
AEgera
AEterna Zentaris
Affymax
Agenus
Aida Pharmaceuticals
Aileron Therapeutics
Allostera
Allosterix
Alnylam
AlphaVax
Altor BioScience
Ambit Biosciences
Ambrilia Biopharma
Amgen
Anadys Pharmaceuticals
Anaphore
Anavex Life Sciences
Anchor Therapeutics
AngioChem
Angstrom Pharmaceuticals
Antisense Pharma
Antisoma
Aphios
AplaGen Biopharmaceuticals
Apogenix
ApopLogic Pharmaceuticals
Apotex
Ardana
Ariad
Arno Therapeutics
ArQule
Array BioPharma
Ascenta Therapeutics
Astellas
Astex Pharmaceuticals
Astex Therapeutics
AstraZeneca
Attenuon
Avila Therapeutics
Basilea Pharmaceutica
Baxter International
Bayer
Bio-Medisinsk Innovasjon
BioAlliance Pharma
BioAxone
Biocad
Biogen Idec
BioInvent
Biokine Therapeutics
BioLineRx
Biomas
Bionovo
BioNTech
BioNumerik
BioSante
Biosceptre
Biotech Ltd
Biotecnol
BioVex
Boehringer Ingelheim
Bristol-Myers Squibb
Camurus
CanBas
Cancer Advances
Cancer Innovations
Cancer Research Technology
CDG Therapeutics
Celecure
Celera
Celgene
Celldex Therapeutics
Celtic Pharma
Cephalon
ChemoCentryx
Chemokine Therapeutics
Chiasma
Chlorogen
Chroma Therapeutics
CJ Corp
Clavis Pharma
Cleveland BioLabs
Clinuvel
CombinatoRx
Compugen
Coronado Biosciences
Cosmo Pharmaceuticals
Critical Outcome Technologies
CSL
Curaxis
CureTech
Curis
Cyclacel
Cylene Pharmaceuticals
Cynvec
CytImmune Sciences
Cytochroma
Cytokinetics
CytRx
Daewoong
Daiichi Sankyo
Dainippon Sumitomo Pharma
Dara Biosciences
Debiopharm
Deciphera Pharmaceuticals
Dendreon
DeveloGen
Digna Biotech
DNAVEC
Dong-A
Dongkook Pharm
Eisai
Eleos
Eli Lilly
Emergent BioSolutions
Endo Pharmaceuticals
Enkam Pharmaceuticals
EntreMed
Enzon
EpiCept
Erimos
Esperance Pharmaceuticals
Exelixis
Flamel Technologies
Formula Pharmaceuticals
Galena Biopharma
Generex
Genmab
GENova Biotherapeutics
Genovax
Genta
GenVec
Gerolymatos
Geron
GlaxoSmithKline
Glide Pharma
Gliknik
GlycoGenesys
Glycotope
GP Pharm
GPC Biotech
Gradalis
Green Cross
Gryphon Therapeutics
Harbor BioSciences
Hemispherx Biopharma
Hoffmann-La Roche
Human Genome Sciences
Ichor Medical Systems
Idera Pharmaceuticals
ImmunoCellular Therapeutics
Immunocore
ImmunoGen
Immunotope
Immunovaccine
ImmuPharma
Incyte Corporation
Infinity Pharmaceuticals
Innate Pharma
InNexus Biotechnology
Innovive
Inotek
Inovio
Insmed
Insys Therapeutics
Intas Biopharmaceuticals
Intracel
Intradigm
Intrexon
Introgen Therapeutics
Ipsen
ISA Pharmaceuticals
Isis Pharmaceuticals
ISU ABXIS
Jennerex Biotherapeutics
Johnson & Johnson
KAEL-GemVax
Kalypsys
Karyon-CTT
Keryx Biopharmaceuticals
Kiadis
Kirax
Kyowa Hakko Kirin
Lee’s Pharmaceutical
Leo
LG Life Sciences
Ligand
Lipotek
Lorus Therapeutics
Mannkind
Marillion Pharmaceuticals
MBiotec
Meda
MediGene
Mediolanum
Medisyn Technologies
Merck & Co
Merck KGaA
MethylGene
Mitsubishi Tanabe Pharma
Mochida
Mojave Therapeutics
MolMed
Mologen
Nektar Therapeutics
Nemod Biotherapeutics
Nereus Pharmaceuticals
Nerviano Medical Sciences
Neurobiological Technologies
Nidus Laboratories
NIH
Nippon Shinyaku
Non-industrial source
Novacea
NovaLead
Novartis
Novelix
Novogen
NPS Pharmaceuticals
Oasmia
Oncalis
Onconova
OncoTherapy Science
Oncothyreon
Oncovir
OSI Pharmaceuticals
Oxford BioMedica
OXiGENE
Pacific Biotech
PanaGin
Patrys
PBL Therapeutics
Pepscan Therapeutics
Peptagen
PepTx
Pfizer
Pharmacyclics
PharmaGap
PharmaMar
Pharmexa
Pharminox
PhiloGene
Pierre Fabre
Piramal
Progen
ProMetic Life Sciences
Protagonist
Q Chip
QLT
Raptor Pharmaceutical
Reata Pharmaceuticals
Receptor BioLogix
Regulon
Reliance Life Sciences
Rexahn
Rigel
Rosetta Genomics
Sanofi
Santaris Pharma
Santhera Pharmaceuticals
Sarepta Therapeutics
Sareum
SBI Biotech
Scancell
SciClone Pharmaceuticals
Seattle Genetics
Semafore Pharmaceuticals
Senesco Technologies
Serometrix
Shire
Sigma-Tau
Simcere Pharmaceuticals
Solbec Pharmaceuticals
Soligenix
Spectrum Pharmaceuticals
Spirogen
SRI International
Sunesis
SuperGen
Swedish Orphan Biovitrum
Switch Pharma
SymBio Pharmaceuticals
Symbiotec
Synta Pharmaceuticals
Tactic Pharma
Takeda
Tapestry Pharmaceuticals
Targa Therapeutics
Targepeutics
Tau Therapeutics
Taxolog
Telik
TetraLogic Pharmaceuticals
Teva
Thallion Pharmaceuticals
Therion Biologics
Theryte
Tigris Pharmaceuticals
Titan Pharmaceuticals
to-BBB
Tolerx
TopoTarget
Tracon Pharmaceuticals
Transgene
UMN Pharma
Unigene
United Biomedical
ValiRx
Vaxil BioTherapeutics
Vaxon Biotech
VBL Therapeutics
Vectura
Velacor Therapeutics
Vertex Pharmaceuticals
Vical
Wilex
VioQuest
Viragen
Viralytics
ViroTarg
VM Discovery
WntResearch
Xerion
Xigen
York Pharma
Zelos Therapeutics
Zensun
A Shortlist of Drugs Included are:
131I-tositumomab
A6
abarelix
ABT-510
AEB071
AEG-35156
AEZS-108
afamelanotide
agatolimod
aldesleukin
ALT-801
alvocidib
AME-133
angiopep+paclitaxel
APG-101
APO-866
ARQ-197
ARRY-438162
AS-101
AS-1411
astuprotimut-r
Auto TAG vaccine
axitinib
bardoxolone methyl
belinostat
bevacizumab
BMS-663513
BMS-936558
bortezomib
bosutinib
Buparlisib
BZL-101
Cabozantinib
canfosfamide hydrochloride
CB-10-01
CBP-501
cenersen
cilengitide
cintredekin besudotox
conatumumab
corticorelin acetate
cositecan
crolibulin
CT-011
dasatinib
decitabine
denenicokin
denileukin diftitox
deslorelin
dinaciclib
dovitinib lactate
dulanermin
E-75
E7449
EMD-273063
emepepimut-S
endostatin
entinostat
enzastaurin hydrochloride
EP-100
epirubicin
everolimus
Exherin
fosbretabulin tromethamine
FPI-01
fresolimumab
ganetespib
ganitumab
gataparsen
gefitinib
glembatumumab vedotin
golvatinib
goserelin
GSK-1120212
GSK-2118436
GT-111
GV-1001
GVAX
GX-301
HE-3235
Her-2/Neu peptides
Hi-8 MEL
histamine dihydrochloride
histrelin
ibritumomab tiuxetan
idronoxil
imatinib mesilate
imetelstat
imMucin
INCB-24360
interferon
interleukin-12
interleukin-2
intetumumab
IPH-1101
ipilimumab
IPP-204106
ISA-P53-01
ispinesib mesylate
JX-594
kahalalide F
L19-IL2
Lambrolizumab
lanreotide
LEE-011
lenvatinib
lestaurtinib
leukemia vaccine
leuprolide
leuprolide acetate
leuprorelin
LGX818
LipoVIL12
litronesib
lonaprisan
lumiliximab
mapatumumab
MDX-1379
MetXia
MGN-1601
MKC-1
MKC-1106-MT
mocetinostat
MORAb-004
motexafin gadolinium
NAFB001
navitoclax
netupitant
nilotinib
noscapine
obinutuzumab
oblimersen sodium
octreotide
octreotide, LAR
ON-01910
Oncohist
OncoVAX
OTS-102
ozarelix
P276-00
panobinostat
pasireotide
pasireotide LAR
PAT-SC1
PBI-1402
PCI-24781
peginterferon alfa-2b
perifosine
pimasertib
plitidepsin
poly-ICLC
polyclonal antibody stimulator
PX-12
quarfloxacin
quinacrine
R-(-)-gossypol
RAF-265
ramucirumab
retaspimycin
rhIFN-alpha
ridaforolimus
rindopepimut
rintatolimod
romurtide
sagopilone
sargramostim
SCIB-1
seliciclib
selumetinib
sotatercept
SPC-2996
ß-lapachone
SU-6668
sunitinib malate
Survivac
talminogene laherparepvec
terameprocol
tesetaxel
thalidomide
thymalfasin
tigapotide triflutate
tigatuzumab
tipifarnib
TL-32711
TM-30339
trabedersen
tremelimumab
triciribine phosphate
TRU-016
vapreotide, immediate-release
velimogene aliplasmid
veliparib
vemurafenib
verubulin
vinflunine ditartrate
vitespen
volasertib
volociximab
vosaroxin
VX-001
XL-147
XL-647
YM-155
zanolimumab

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Melanoma, Apoptosis and Peptides.
    To find out more about Triple Analysis: Melanoma, Apoptosis and Peptides, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Melanoma, Apoptosis and Peptides is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Triple Analysis' category:


Triple Analysis: Pancreatic Cancer, Cancer Vaccines and Peptides
This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Pancreatic Cancer), one mechanism/target/effect area (Cancer Vaccines) and one compound specific area (Peptides). Learn More


Triple Analysis: Lymphoma, Prostate Cancer and Antibodies
This triple analysis focuses on cancer drug development strategies in both Lymphoma and Prostate Cancer and by the compound strategy of Antibodies. Learn More

Other selected research from the 'Oncology' category:


Triple Analysis: Colorectal Cancer, Lung Cancer and Lymphoma
This triple analysis focuses on cancer drug development strategies in Colorectal Cancer, Lung Cancer and Lymphoma. Learn More


Conjugated Drugs in Oncology: Drug Pathway Analyzer
There are today at least 394 conjugated drugs known to affect more than 211 specific intracellular signaling pathways for the treatment of more than 109 different tumor types. The rational for this plethora of treatment strategies is based on our increasing understanding of the 211 drug targets that are included in this drug-pathway analyzing tool. No less than 190 of these have been recorded with mutations and 36 drug targets have mutations which have been causally implicated in cancer. Learn More